Used in pharmaceutical research as a key intermediate in the synthesis of tyrosine kinase inhibitors, particularly in the development of targeted cancer therapies. It exhibits potential in inhibiting specific signaling pathways involved in tumor growth and progression. Due to its structural features, it enhances selectivity and binding affinity toward epidermal growth factor receptor (EGFR) mutants. Commonly employed in the preparation of active pharmaceutical ingredients (APIs) for non-small cell lung cancer (NSCLC) treatments. Also utilized in structure-activity relationship (SAR) studies to optimize potency and pharmacokinetic properties of oncology drug candidates.